Local biotech invests in erectile dysfunction drug

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

The company – which specializes in repurposing drugs already approved for other purposes – has signed a letter of intent to license a sublingual formation for drugs used to treat erectile dysfunction. Sublingual formations (which allow drugs to be dissolved under the tongue) absorb more quickly and therefore take effect sooner.

"We expect to move this product through pivotal trials and through regulatory approval over the next year and intend to begin marketing within two years," said Pacific Therapeutics CEO Douglas Unwin.

"We expect to complete the license in the first quarter of 2013, and move rapidly to the late-stage clinical trials and marketing."

In 2006, the market for drugs for treating erectile dysfunction exceeded $3 billion, the company said.

Pacific Therapeutics has two other drugs in the pipeline, both of which are for the treatment of scarring of human tissue.

Its lead product, PTL-202, is a combination of drugs being tested for efficacy in treating idiopathic pulmonary fibrosis, a progressive scarring of the lungs. The drug is already approved by the Food and Drug Administration in the U.S. and is currently in stage one of clinical trials.

nbennett@biv.com

@nbennett_biv

comments powered by Disqus

Also Read

More From Innovation

Tyler Orton discusses Apple stocks jumping in after-hours trading

Read Article

Tech companies helping keep data pirates and identity thieves at bay  

Read Article

Fast-growing Vancouver companies compete to make in-house HR software   

Read Article

UBC and SFU have churned out more than 200 spinoffs the past 30 years, but as many as a quarter haven’t survived 

Read Article

Students in elementary school today were all born at a time when having the Internet in one’s home was a given.  

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×